{"id":"W2164257516","doi":"10.3109/10428194.2014.893304","title":"Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for the treatment of secondary plasma cell leukemia","year":2014,"lang":"en","type":"letter","venue":"Leukemia & lymphoma/Leukemia and lymphoma","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Bortezomib; Plasma cell leukemia; Dexamethasone; Medicine; Multiple myeloma; Pharmacology; Leukemia; Oncology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003687067,0.0005784142,0.0007013782,0.0005178393,0.001537809,0.0008691682,0.0009015421,0.006323248,0.00436973],"category_scores_gemma":[0.002099689,0.0002412105,0.0007833115,0.0005415544,0.0009547021,0.001320403,0.0005121029,0.007708088,0.003867658],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002745048,"about_ca_system_score_gemma":0.001332859,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002207384,"about_ca_topic_score_gemma":0.006317698,"domain_scores_codex":[0.9994634,0.0001364917,0.00005856532,0.0000721942,0.000175778,0.00009362924],"domain_scores_gemma":[0.9995689,0.0001554536,0.00005087595,0.00002159844,0.00006707709,0.0001361531],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003775704,0.0003323168,0.006092289,0.000401766,0.00007000942,0.2355722,0.0002561741,0.0005523006,0.003296122,0.007742194,0.6453866,0.09992042],"study_design_scores_gemma":[0.000436359,0.0005798743,0.005025381,0.0006370799,0.0000697153,0.3616659,0.000302513,0.001959432,0.001336203,0.01163662,0.6162949,0.00005600394],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.02241924,0.02885955,0.002062745,0.860337,0.02375335,0.0002605855,0.00031328,0.0003022538,0.06169211],"genre_scores_gemma":[0.2338425,0.04460787,0.004508619,0.5749326,0.07224037,0.0002328039,0.0004255637,0.0001253919,0.06908435],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.006323248,"threshold_uncertainty_score":0.01991683,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02423733210581714,"score_gpt":0.2679509948797453,"score_spread":0.2437136627739281,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}